C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $7.6667.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a report on Friday, July 17th.

Institutional Trading of C4 Therapeutics

Several institutional investors have recently added to or reduced their stakes in CCCC. Squarepoint Ops LLC lifted its holdings in C4 Therapeutics by 320.1% in the second quarter. Squarepoint Ops LLC now owns 170,834 shares of the company’s stock valued at $798,000 after buying an additional 130,170 shares during the period. Seven Fleet Capital Management LP raised its position in shares of C4 Therapeutics by 567.8% in the 2nd quarter. Seven Fleet Capital Management LP now owns 381,169 shares of the company’s stock worth $1,780,000 after acquiring an additional 324,093 shares in the last quarter. Velan Capital Investment Management LP bought a new position in shares of C4 Therapeutics in the 2nd quarter worth about $2,662,000. Headlands Technologies LLC acquired a new position in shares of C4 Therapeutics in the 2nd quarter valued at about $719,000. Finally, Wellington Management Group LLP acquired a new position in shares of C4 Therapeutics in the 2nd quarter valued at about $1,064,000. 78.81% of the stock is currently owned by institutional investors.

C4 Therapeutics Trading Down 0.6%

Shares of CCCC stock opened at $3.39 on Monday. The firm has a market capitalization of $417.07 million, a price-to-earnings ratio of -3.39 and a beta of 2.94. The business’s 50-day moving average price is $3.75 and its 200-day moving average price is $3.49. C4 Therapeutics has a 12 month low of $1.69 and a 12 month high of $5.17.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative return on equity of 45.45% and a negative net margin of 289.44%. On average, sell-side analysts predict that C4 Therapeutics will post -0.85 earnings per share for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to recruit the body’s natural protein-disposal system to remove specific proteins rather than simply inhibit their activity.

C4 Therapeutics develops its drug candidates through its proprietary TORPEDO platform, which is intended to identify and optimize small-molecule degraders for challenging biological targets.